AIRT Form 4—Director Trade: 982 Shares Sold; Two 500-Share Options Granted
Rhea-AI Filing Summary
Travis Jacob Swenson, a director of Air T Inc. (ticker shown as AIRT), reported transactions on Form 4 dated 08/11/2025 with a filing signature on 08/14/2025. The filing shows a disposition of 982 shares of Common Stock and two derivative transactions: two grants of stock options for 500 shares each (exercise prices listed as $30 and $50) dated 08/11/2025 that become exercisable on 08/06/2026 and expire on 08/06/2045. Following the reported option grants, the filing shows 500 underlying shares for each option grant held directly. The explanatory note states that unvested options from December 2020 remain subject to price-tranche vesting and expirations and that 1,500 options are currently outstanding after prior expirations.
Positive
- Director received two long-dated stock option grants (500 shares each) which align executive incentives with long-term stock performance
- Filing includes an explanatory note clarifying vesting mechanics and current outstanding option totals (1,500), improving transparency
Negative
- Disposition of 982 common shares by the director on 08/11/2025 could be perceived as insider selling
- Earlier option grants have complex price-tranche vesting and automatic expirations, which may reduce future upside for insiders if price hurdles are not met
Insights
TL;DR: Director sold 982 shares and received two 500-share option grants, creating a mixed signal on insider activity.
The disposal of 982 shares on the same date as two option grants is noteworthy but not conclusive. The grants are long-dated (expiring 2045) with exercisable dates in 2026 and strike prices of $30 and $50, which suggests a long-term incentive structure. The explanatory note confirming 1,500 outstanding options clarifies dilution potential from legacy awards. For valuation impact, the transactions are routine director compensation and do not by themselves change company fundamentals.
TL;DR: Standard director awards and a share disposition were reported; vesting conditions include price-based tranches tied to market testing dates.
The Form 4 discloses two option awards to a director and a contemporaneous sale of shares. The filing explicitly describes complex vesting for earlier awards tied to achievement of trading-price thresholds with automatic expirations if thresholds are not met. This disclosure is administratively important for transparency around insider compensation and outstanding dilutive instruments but does not allege any governance irregularity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock options | 500 | $0.00 | $0.00 |
| Grant/Award | Stock options | 500 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Cumulative amount does not include presently unexerciseable options granted in December 2020. Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount currently outstanding is 1,500. For further details, see the Company's proxy statement filed July 3, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
